In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.
It's no secret that the immunology space for biosimilars is growing and growing fast, with between 8 and 10 adalimumab biosimilars and at least 2 ustekinumab biosimilars expected to launch in the United States throughout 2023. In light of 2 of the most profitable originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity around the same time, 3 doctors in the immunology space penned a 3-article supplement in The American Journal of Managed Care® entitled "Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update."
The Center for Biosimilars®, the sister website of The American Journal of Managed Care®, is conducting a multimedia interview series with the authors to expand on some of the information presented in the supplement. On this episode of Not So Different, we spoke with Vibeke Strand, MD, one of the co-authors and an adjunct clinical professor in the Division of Immunology/Rheumatology at Stanford University School of Medicine. We discussed the article "Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence" as well as how health systems can take charge and try to boost biosimilar adoption.
Show notes
To read all the articles within the supplement, click here.
To read the article references in this episode, click here.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs
July 31st 2025Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.
Escaping the Void: All Things Biosimilars With Craig & G
July 31st 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."